ChemoCentryx (CCXI) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to ChemoCentryx (CCXI) Misses Q1 EPS by 7c
May 12, 2016 8:54 AM EDT
ChemoCentryx, Inc., (Nasdaq: CCXI) announced that preclinical data using a series of orally-available inhibitors of the chemokine receptor known as CCR6, have been selected for a poster presentation at the 2016 Society for Investigational Dermatology Annual Meeting, being held May 11-14, 2016 in Scottsdale, Arizona.
Poster Presentation:
Title: Chemokine Receptor Inhibition as a Novel Therapeutic Approach for Psoriasis (Abstract No. 521) Session Title: Poster Session I Session Date & Time: Thursday, May 12, 2016, 10:15 AM - 12:15 PM MST Location: Herberger Ballroom, The Westin Kierland Resort &... More
May 10, 2016 6:43 AM EDT
Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq: CCXI), a biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, announced today that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor ready for Phase 3 development for orphan and rare renal diseases, in Europe, Canada, Mexico, Central and South America and South... More
